American Society of Hematology/LinkedIn
Oct 1, 2026, 14:39
Understanding the FDA Pathway for Hematology Product Development – American Society of Hematology
American Society of Hematology shared a post on LinkedIn:
“Over the past two days, ASH and the FDA convened the ASH-FDA Collaboration: Workshop on Regulatory Science in Hematology, an interactive program designed to deepen participants’ understanding of the FDA’s role in hematology product development.
Participants explored the FDA’s role in hematology product development through dynamic panels, case studies, and discussions on the IND process, clinical trial design, expanded access, expedited development programs, and regulatory review.
Learn more about the workshop.”
Other posts featuring American Society of Hematology on Hemostasis Today.
-
Oct 1, 2026, 15:44A Century of Von Willebrand Disease Awareness – EHC
-
Oct 1, 2026, 15:31Andreas Calatzis: The Power of Teamwork in Postpartum Hemorrhage
-
Oct 1, 2026, 15:09Halimat Olaniyan: The Role of Transfusion Medicine in Sickle Cell Disease Care
-
Oct 1, 2026, 14:58Samir Kumar Beura: Modern Approaches to Platelet Structure and Function
-
Oct 1, 2026, 13:56Ravi C Dara: Advancing Red Cell Exchange in Sickle Cell Disease
-
Oct 1, 2026, 13:50Mateo Marin-Cuartas: What Matters After Aortic Valve Replacement in Younger Patients?
-
Oct 1, 2026, 13:17Anirban Sen Gupta: Sharing Ideas, Advancing Biomedical Innovation
-
Oct 1, 2026, 13:01Michael Honigberg: Clonal Hematopoiesis as a Driver of Aortic Valve Calcification
-
Oct 1, 2026, 12:22Augustina Isioma Ikusemoro: Kell Blood Group System – Clinical Significance and Transfusion Practice